Allergan R&D Innovations Recognized with Three Nominations for the 2014 U.S. Prix Galien Awards
Monday, August 04, 2014 | Practice Development
Allergan announced that the company's research and development pipeline has been recognized by the Galien Foundation, which has nominated three of Allergan's products for the 2014 U.S. Prix Galien Awards, according to a company news release. The Prix Galien Award is considered the biomedical industry’s highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.
The Allergan products that have been nominated for the 2014 U.S. Prix Galien Awards are:
• Best Biotechnology Product Nominee - Botox (onabotulinumtoxinA) for Chronic Migraine patients
• Best Pharmaceutical Agent Nominee - Ozurdex (dexamethasone intravitreal implant) 0.7 mg
• Best Medical Technology Nominee - Seri Surgical Scaffold
“For more than 64 years, Allergan has remained committed to developing innovative products to address unmet medical needs,” said David E.I. Pyott, Chairman and Chief Executive Officer, Allergan. “We are proud to be recognized for our R&D efforts by the Prix Galien Committee and especially honored to be the only company to receive nominations in all three of the 2014 Prix Galien Award categories.”
Recipients of the Prix Galien Awards will be announced at the Prix Galien USA Award Ceremony in New York this fall and are selected by a committee of 10 leaders from the biomedical industry and academia, including five Nobel Laureates.
“Innovation is a key measure of Allergan’s commitment to R&D,” said Scott M. Whitcup, MD, Executive Vice President, Research and Development, Chief Scientific Officer, Allergan. “With a focus on basic research and clinical development in our specialty areas, we are able to bring novel treatments to market that benefit patients, and are pleased to be recognized by the Galien Foundation for three of these products.”
In the United States, Botox is currently approved for eight medical conditions, including Chronic Migraine, a disease affecting approximately 3.2 million Americans. Botox is the first and only preventive treatment approved by the FDA to reduce headache days every month for adults with Chronic Migraine — 15 or more headache days a month with headache lasting 4 hours or more. Botox is similarly indicated for the treatment of Chronic Migraine in 64 countries.
Ozurdex is a biodegradable steroid implant that uses the proprietary and innovative Novadur solid polymer delivery system to release medicine over an extended period of time. The Ozurdex implant is approved for three ophthalmic indications in the United States, including for the treatment of non-infectious inflammation of the uvea (uveitis) affecting the back of the eye, for which it is nominated by the Galien Foundation for Best Pharmaceutical Agent. Most recently, Allergan received FDA approval June 30 of Ozurdex for the treatment of diabetic macular edema in patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic).
Seri Surgical Scaffold is a sterile, silk-derived bioprotein, ultrapurified using the Biosilk process. This unique product is the first and only silk-derived biological scaffold cleared by the FDA for reinforcement of soft tissue in plastic and reconstructive surgery.
You must be logged in to leave a comment.